about
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationEuropean perspective on multiple myeloma treatment strategies in 2014TGF-β - an excellent servant but a bad masterExtramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression dataCombining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE studyThe clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatmentGenome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience.Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.Mechanism of immunomodulatory drugs in multiple myeloma.Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.Shared structural features of the 9aaTAD family in complex with CBP.Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment.International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.European Myeloma Network guidelines for the management of multiple myeloma-related complications.Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myelomaCarfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR studyCirculating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance
P50
Q27002668-FD5418F5-C0D2-4D77-896F-64FB9979F3ADQ27005966-43E09166-89F3-44A9-9A05-01265A7F94A6Q27025590-6FBBC186-6507-467C-8921-EE47F142BB6AQ28260508-5BB86A2D-4A0F-41AB-8B54-F1971B8D13D0Q30571858-F698E042-E181-4A8D-9020-E141B668B6DCQ30615908-92E35D50-4C45-440E-8302-E6D9B8605836Q30756778-3A96BF03-AD6F-44F6-A865-61FBE712B043Q31094748-8B310218-AE89-43F3-8FE5-0D1889F10240Q33391788-4A583A14-49F9-4754-A234-1264D8B3F661Q33410481-BD1642A7-2635-406F-A2CE-7FA65E038BB4Q33433893-86D5385B-1070-4835-B1AB-AD646C13E1C8Q33441702-60C598B1-57F4-4F8D-ACE1-81A0E1B93581Q33626064-E5AB236A-386A-4586-8629-1814614862A8Q33695919-CD6D437F-EE0A-41D9-B0D2-EEDF952FC3F9Q33701834-B58DF37E-9786-4EE4-9B80-4127B92F18D8Q33768000-C36D6390-AE59-4DA2-9DB2-0469D5024730Q33785935-788F2C08-5A35-41BF-94A0-52ED6A85941BQ33860782-EBB96284-9AB2-43DF-9C4A-149D1268EE1BQ33956990-AAF8B186-E677-412C-A84F-A5E66F134A3AQ34049802-807537E0-545C-441E-9E06-6A8ACEE2EC4EQ34095653-6BA3B417-2233-49C1-B5D8-CDC754147A53Q34111475-7B8CA6A1-4C05-4374-836E-C16D3376B45EQ34283697-02EFFB43-7A11-430C-875A-FA1F56F95E7FQ34447864-D81BAE97-33D0-4B8A-9B59-5A1E49F5ABB1Q34456840-69924634-0AEA-454B-81DD-A069A216E3BFQ34478019-EC2ACCF5-A21D-42AE-B85F-53C9392E834DQ34884527-F0E15471-E60E-4CD2-9F3B-4DC53B6C2270Q35220639-DDD92BB6-B0D9-43FF-B374-E3C44030CCF4Q35759705-DE90848F-B121-4049-AC4A-7C7C97E436E4Q35781800-E5DB2DE9-5180-4126-8784-CDEF3B4B5765Q36115636-216C6AD2-5EAA-4720-A8F0-F0AF06E8C53BQ36592788-060B0B2A-8E1B-4C52-8CA4-462CFF958D5DQ36738814-7A107627-7965-4308-B61C-9B80CB026250Q37228327-571B0581-74BB-495B-8E1B-30F18CCC944FQ37507513-827B54F1-9538-4EEB-A8BA-B44EC2064ED1Q37530452-0EAA39D0-FF0B-406C-9682-D26889137C1DQ37552008-C420A234-C53F-44A2-A52A-B30CCD4DA355Q37552061-BA2041EE-2A66-4592-B029-BC9F4B19C1EDQ37570630-FB555412-4F94-4C5B-A941-89D45CB0EA7FQ37618914-01EC90B1-C5DB-4FF6-B8A0-B28E8C6C1BBD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roman Hajek
@ast
Roman Hajek
@en
Roman Hajek
@es
Roman Hajek
@nl
type
label
Roman Hajek
@ast
Roman Hajek
@en
Roman Hajek
@es
Roman Hajek
@nl
prefLabel
Roman Hajek
@ast
Roman Hajek
@en
Roman Hajek
@es
Roman Hajek
@nl
P214
P106
P214
P31
P496
0000-0001-6955-6267
P569
1964-01-01T00:00:00Z
P691
nlk20000083645
P7859
viaf-84793871